Thu, Jul 10, 2014, 2:34 AM EDT - U.S. Markets open in 6 hrs 56 mins


% | $
Quotes you view appear here for quick access.

MannKind Corp. Message Board

brentie98 4 posts  |  Last Activity: Jun 23, 2014 11:12 AM Member since: Jan 14, 2009
SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • Reply to

    The Gospel according to Scott Matusow

    by gord111738 Jun 23, 2014 8:57 AM
    brentie98 brentie98 Jun 23, 2014 11:12 AM Flag

  • brentie98 brentie98 Jun 3, 2014 5:49 PM Flag

    Matthew Pfeffer - Corporate Vice President and Chief Financial Officer
    So, Graig, I think you can safely assume that from what we can hear so I can just kind of recap. We will all be there and there will be some presentations that we will be giving at ADA. So we all will be around. The question is just whether we have a booth on the floor or not but we will still be pretty actively involved at the ADA.

    Alfred Mann - Chairman of the Board, Chief Executive Officer
    We would like to have booth. The problem is that if we cannot open discussions, it's probably is worth spending the money and we can't have open discussions unless we have approval sometime and probably days if not weeks before the ADA meeting and we have no guarantee of that.

  • Reply to

    Why ?

    by mapconn May 16, 2014 6:09 PM
    brentie98 brentie98 May 16, 2014 9:52 PM Flag

    Gambler, I had that problem a while back. It was Internet Explorer, I switched to Google Chrome and the problems disappeared.

  • Reply to


    by incel1 May 8, 2014 11:10 AM
    brentie98 brentie98 May 8, 2014 11:40 AM Flag

    incel1, on your point 6...

    MannKind Closes Acquisition of Insulin Assets from Pfizer
    VALENCIA, Calif.--(BUSINESS WIRE)--Jun. 22, 2009-- MannKind Corporation (Nasdaq:MNKD) today announced that it has completed its acquisition from Pfizer Inc. (NYSE:PFE) of a quantity of bulk insulin and a license to manufacture bulk insulin for use in pulmonary delivery pursuant to an insulin sale and purchase agreement. Upon the closing, MannKind and Pfizer also entered into an agreement pursuant to which MannKind agreed to maintain and store the remainder of Pfizer’s bulk insulin inventory and acquired an option to purchase the remaining insulin, in whole or in part, at a specified price, to the extent that Pfizer has not otherwise disposed of or used the remaining insulin. The total purchase price for this transaction, including consideration payable to MannKind for its storage and maintenance obligations, was $3 million, which MannKind paid in cash.

    MannKind had also entered into a sale and purchase agreement with Pfizer relating to Pfizer’s insulin manufacturing facility in Frankfurt, Germany. MannKind’s rights and obligations under this latter agreement were subject to a right of first refusal in favor of Sanofi-Aventis. On June 8, 2009, Sanofi-Aventis exercised its right of first refusal, thereby releasing MannKind from any obligations under this agreement.

9.94+0.25(+2.58%)Jul 9 4:00 PMEDT

Trending Tickers

Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.